HP568 + palbociclib

HP568 + palbociclib is an investigational combination therapy being studied for the treatment of estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2-) locally advanced or metastatic breast cancer. Palbociclib is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), which are key regulators of cell cycle progression. By inhibiting CDK4/6, palbociclib prevents phosphorylation of the retinoblastoma protein, thereby blocking cell cycle progression from G1 to S phase and inhibiting cancer cell proliferation[3][5][6][8]. HP568 is an oral investigational agent currently in Phase 1/2 clinical trials; its precise mechanism has not been publicly disclosed as of now[4][7]. The combination aims to enhance antitumor efficacy in ER+/HER2- breast cancer patients.